Q32 Bio to Participate in Upcoming September Investor Conferences
Q32 Bio will outline progress on its alopecia areata program and other clinical work during three investor conferences this month.
- Q32 Bio Inc. announced on Tuesday that management will participate in three upcoming investor conferences throughout September 2026 to discuss company progress in autoimmune disease treatments.
- The clinical-stage biotechnology firm focuses on developing innovative therapies for autoimmune and inflammatory diseases, currently advancing bempikibart through an ongoing Phase 2 program.
- Management will present at the Cantor Global Healthcare Conference in New York on September 9, with a follow-up appearance at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15.
- Live audio webcasts of each presentation will be accessible through the company website, where archived replays remain available for 90 days following each event.
- Approximately 700,000 people in the United States live with alopecia areata, a disease presenting limited treatment options that underscores the firm's research focus and market opportunity.
22 Articles
22 Articles
Morgan County Citizen
inovio.comINOVIO to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in…
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will…
North Bay Nipissing
Financial PostProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences…
BridgeBio to Participate in September Investor Conferences
PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate…
Q32 Bio to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate…
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
